# Febrile Neutropenia

Febrile neutropenia is an oncologic emergency requiring immediate empiric antibacterial therapy, focused source evaluation, and disposition based on physiologic stability, anticipated neutropenia, and validated complication-risk assessment.

**Clinical question:** How should clinicians rapidly evaluate, risk-stratify, and treat adults and children with febrile neutropenia?

Updated: 2026-08-24T17:31:18.523169+00:00

## What matters in practice
- Treat fever with ANC 500/µL or lower, or ANC expected to fall to 500/µL or lower within 48 hours, as febrile neutropenia; a single oral temperature of 38.3°C or higher or temperature of 38.0°C or higher sustained for 1 hour meets the fever threshold.[1][19]
- Administer empiric antibacterial therapy urgently, within 2 hours of presentation, rather than waiting for culture results or a localizing source.[19]
- Use clinical condition, cancer therapy context, baseline studies, and risk assessment to distinguish patients requiring inpatient treatment from carefully selected low-risk candidates for outpatient management.[1][13][23]
- Persistent fever after approximately 1 week of broad-spectrum antibacterial therapy during ongoing neutropenia should prompt consideration of empiric antifungal therapy and evaluation for invasive fungal infection.[8][20]
- Fever after chemotherapy remains high risk even when a bacterial source is not apparent; recent chemotherapy within 6 weeks should heighten suspicion for treatment-related neutropenia.[15]

## Recognize febrile neutropenia and give antibiotics urgently

Do not defer treatment while confirming an infectious source.

Diagnose febrile neutropenia when oral temperature is at least 38.3°C (101°F) once, or at least 38.0°C (100.4°F) sustained for 1 hour, with ANC 500/µL or lower, or ANC 1,000/µL or lower that is expected to decrease to 500/µL or lower within 48 hours.[1][19] This threshold includes patients at the anticipated chemotherapy nadir, not only those with an already documented ANC below 500/µL.

Treat febrile neutropenia as an oncologic emergency. Obtain clinically indicated diagnostic specimens promptly, but administer empiric antibacterial therapy within 2 hours of presentation; microbiologic confirmation is not required because many episodes have no identifiable bacterial source despite the need for antibacterial treatment.[1][15][19]

Prioritize physiologic stabilization before outpatient-risk assessment. Hemodynamic instability, respiratory compromise, altered mental status, or other features of critical illness should direct immediate inpatient escalation and broad empiric treatment rather than use of a low-risk pathway. Septic shock and comorbidity substantially increase reported mortality risk in febrile neutropenia.[23]
- Confirm temperature method, timing, and peak value; use the oral fever thresholds when applying the standard definition.[1][19]
- Calculate ANC and determine whether the count is expected to decline during the next 48 hours.[1][19]
- Document timing and type of systemic anticancer therapy; chemotherapy received within 6 weeks of presentation increases the likelihood of treatment-associated neutropenia.[15]
- Draw cultures and collect urine, wound, or other site-directed specimens when clinically indicated, but do not allow collection to delay empiric antibiotics.[12][19]

*Operational diagnostic thresholds for febrile neutropenia.[1][19]*

| Finding | Threshold | Clinical action |
| --- | --- | --- |
| Fever | Single oral temperature ≥38.3°C (101°F), or ≥38.0°C (100.4°F) sustained for 1 hour.[1][19] | Evaluate immediately for febrile neutropenia when neutropenia is present or anticipated.[1][19] |
| Established severe neutropenia | ANC ≤500/µL.[1][19] | Treat fever as febrile neutropenia and initiate urgent empiric antibacterial therapy.[19] |
| Anticipated severe neutropenia | ANC ≤1,000/µL expected to fall to ≤500/µL within 48 hours.[1][19] | Use the same emergency management pathway as established severe neutropenia.[1][19] |

## Perform a focused source evaluation without delaying treatment

Testing should identify instability, an actionable focus, and therapy-limiting organ dysfunction.

Perform a complete examination targeted to occult infection sites and treatment complications, including the oral cavity, skin and soft tissue, vascular-access sites, perineum, lungs, abdomen, and wounds. In neutropenic patients, local inflammatory findings may be limited; absence of a clear source does not reduce the need for empiric antibacterial treatment.[15][19]

Obtain a complete blood count with differential to establish ANC and assess concurrent cytopenias. Measure renal function, liver tests, and electrolytes because these define acute organ involvement and provide a baseline for antimicrobial selection and subsequent toxicity monitoring. Blood cultures should include a peripheral sample; obtain urine, wound, or pus cultures when those sites are clinically implicated.[12]

Use imaging selectively rather than as a universal screening test. Obtain chest imaging for respiratory symptoms or signs; high-resolution chest CT is used when fungal infection is clinically suspected. In persistent neutropenic fever, imaging and microbiology should be revisited because an initially occult invasive fungal process may emerge after broad-spectrum antibacterial exposure.[12][20]
- Bloodstream infection evaluation: obtain peripheral blood culture and add cultures from clinically relevant sites or access devices according to presentation.[12]
- Urinary or wound focus: obtain urine culture or wound/pus culture when symptoms, examination, or device findings support that source.[12]
- Pulmonary or fungal concern: use chest imaging for clinical pulmonary findings and high-resolution chest CT when invasive fungal infection is suspected.[12]
- Biomarkers: procalcitonin has been studied for bacteremia, ICU admission, and mortality prediction, but should complement rather than replace clinical assessment and cultures.[23]

*Focused initial studies and the decision each study informs.[12][23]*

| Study | When to obtain | Decision informed |
| --- | --- | --- |
| CBC with differential | At presentation.[12] | Confirms ANC category, detects concurrent cytopenias, and establishes a baseline for serial monitoring.[1][12] |
| Renal function, liver tests, electrolytes | At presentation.[12] | Identifies organ dysfunction and provides a baseline for antimicrobial selection and monitoring.[12] |
| Peripheral blood culture | At presentation before or during urgent treatment workflow.[12][19] | Identifies bacteremia and supports later antimicrobial targeting; do not delay empiric therapy.[19] |
| Urine or wound/pus culture | When urinary, wound, or soft-tissue findings are present.[12] | Defines an actionable source and susceptibility profile.[12] |
| Chest imaging; high-resolution chest CT | For respiratory findings; use high-resolution CT when fungal infection is suspected.[12] | Identifies pulmonary infection and supports escalation to an invasive fungal infection pathway.[12][20] |

## Separate high-risk episodes from selected outpatient candidates

Clinical stability is the first gate; prediction tools refine, but do not replace, bedside assessment.

Risk stratification should integrate current clinical condition, cancer type and treatment context, infection history, baseline laboratory and radiographic findings, and anticipated duration or depth of neutropenia. Talcott, MASCC, and CISNE are established adult complication-risk models, but they use different predictors and should be interpreted within the presenting clinical context.[11][13][23]

High-risk management is appropriate for patients with physiologic instability, severe clinical illness, major comorbidity, concerning vital-sign or laboratory abnormalities, or a presentation requiring inpatient diagnostic or supportive care. These patients should receive inpatient empiric antibacterial therapy and serial reassessment for a source, resistance, organ dysfunction, and escalation needs.[11][23]

Outpatient management is a risk-stratified option rather than a default. ASCO/IDSA guidance addresses outpatient treatment in adults with malignancy, and evidence supports reduced-intensity treatment for selected low-risk pediatric episodes; selection depends on a structured low-risk assessment and the ability to safely execute follow-up and reassessment.[1][2][5][13][23]
- Do not classify a patient as low risk solely because no source is identified; unknown-source fever is common in febrile neutropenia.[15][21]
- Use MASCC, CISNE, or Talcott only after determining that the patient is clinically stable enough for risk-based disposition assessment.[11][23]
- Reassess risk when vital signs, organ-function studies, cultures, imaging, or neutrophil trajectory change; a low-risk designation at triage is not permanent.[11][13][23]

### Pediatric episodes

For children with cancer or hematopoietic stem-cell transplantation, initial assessment similarly relies on history, examination, baseline laboratory and radiologic studies, and clinical condition. Pediatric low-risk pathways can reduce treatment intensity in selected episodes, but require a pediatric oncology-specific risk framework rather than direct application of adult disposition tools.[2][5][13][21]

*Disposition framework for febrile neutropenia.[11][13][23]*

| Clinical branch | Features driving the branch | Next action |
| --- | --- | --- |
| Unstable or clinically high risk | Critical illness, comorbidity, abnormal vital signs or laboratory findings, or need for inpatient diagnostic and supportive management.[11][23] | Admit, provide urgent empiric antibacterial therapy, and reassess serially for complications and source control needs.[19][23] |
| Clinically stable adult | No immediate instability; use clinical context plus an adult complication-risk model such as MASCC, CISNE, or Talcott.[11][23] | Consider outpatient management only if structured assessment supports low risk and safe follow-up is feasible.[1][23] |
| Clinically stable child | Use pediatric oncology history, examination, baseline studies, and pediatric risk stratification.[2][5][13] | Use a pediatric oncology-directed reduced-intensity or outpatient pathway only for a validated low-risk episode.[2][5][21] |

## Use empiric antibacterial therapy first, then escalate by trajectory

Initial therapy is urgent; subsequent changes should follow clinical deterioration, microbiology, and duration of fever.

All patients meeting febrile neutropenia criteria require urgent empiric antibacterial therapy. The immediate objective is early coverage of likely bacterial pathogens during severe neutrophil impairment, not proof of infection before treatment. The guideline timing target is within 2 hours of presentation.[19]

Antibiotic selection should be informed by risk category, current clinical severity, prior infection history, local resistance patterns, and suspected site of infection. The clinical picture should guide antibiotic choices after risk stratification; culture and susceptibility results then permit narrowing or redirection when an organism or focus is established.[3][12][19]

Persistent fever alone during ongoing neutropenia does not establish antibacterial failure, but it requires repeat assessment for a missed focus, resistant pathogen, drug fever, mucosal-barrier injury, and invasive fungal infection. If fever persists after about 1 week of broad-spectrum antibacterial therapy during neutropenia, add empiric antifungal therapy or pursue a preemptive antifungal strategy guided by clinical and diagnostic findings.[8][20]
- At each reassessment, review culture results, renal and hepatic function, new focal findings, and respiratory status before altering therapy.[12][19]
- Escalate fungal evaluation when persistent fever is accompanied by pulmonary findings or other clinical suspicion; high-resolution chest CT is a relevant diagnostic test in this branch.[12][20]
- Use a documented organism, susceptibility profile, or focal infection to replace purely empiric treatment with targeted therapy when clinically appropriate.[12]

### Persistent fever during neutropenia

The clinically important timing discriminator is persistent fever after roughly 7 days of broad-spectrum antibacterial treatment in a neutropenic patient. At that point, reassess for invasive candidiasis and other fungal disease and consider empiric antifungal treatment; diagnostic strategy should be intensified when clinical findings suggest a localized fungal process.[8][20]
- Repeat focused examination and source-directed cultures when a new localizing sign develops.[12]
- Obtain high-resolution chest CT when invasive fungal infection is clinically suspected.[12]
- Do not treat persistent fever as a reason to abandon risk assessment; deterioration, organ dysfunction, or new imaging abnormalities changes the treatment setting and diagnostic urgency.[11][20][23]

*Trajectory-based management after initial empiric antibacterial therapy.[8][12][19][20]*

| Clinical trajectory | Interpretation | Next step |
| --- | --- | --- |
| At presentation | Febrile neutropenia is an oncologic emergency regardless of whether a source is evident.[1][19] | Obtain indicated cultures and baseline studies, then administer empiric antibacterial therapy within 2 hours.[12][19] |
| Culture-positive or source identified | Microbiology or a focal syndrome provides a target for therapy.[12] | Direct treatment to organism susceptibility and site while monitoring clinical response and organ function.[12] |
| Persistent fever during ongoing neutropenia | Consider occult source, resistant infection, and invasive fungal infection; fever alone is not microbiologic proof of antibacterial failure.[8][20] | Repeat focused evaluation; use chest CT when fungal infection is suspected.[12][20] |
| Persistent fever after about 1 week of broad-spectrum antibiotics | This is the traditional trigger for empiric antifungal treatment in a neutropenic patient.[8] | Add empiric antifungal therapy or use a diagnostic-guided preemptive approach when clinical findings support it.[8][20] |

## Monitor for evolving infection and address recurrence risk before the next treatment cycle

Reassessment is driven by clinical trajectory, organ function, microbiology, and future chemotherapy exposure.

Monitor serial vital signs, clinical examination findings, ANC trajectory, renal and hepatic function, and culture results. Reassess promptly for new pulmonary, skin, catheter-associated, urinary, abdominal, or wound findings because the source may be absent at presentation and later become clinically apparent.[12][15]

Before the next chemotherapy cycle, review the episode in the context of regimen-associated febrile neutropenia risk and patient factors. Risk for febrile neutropenia varies with chemotherapy regimen intensity and is modified by age, cancer type, comorbidities, prior infection history, delayed antibiotic exposure, and vital-sign or laboratory abnormalities.[11][16][22]

A prior febrile neutropenia episode should prompt coordination between oncology and the treating acute-care team to document the episode’s severity, microbiology, suspected source, duration of neutropenia, and treatment complications. These data determine whether subsequent cycles require modification of the supportive-care plan or more intensive surveillance; the specific intervention should follow the planned regimen and oncology protocol.[11][16]
- Trend ANC rather than relying on a single count; anticipated decline to severe neutropenia is part of the diagnostic definition.[1][19]
- Trend renal and hepatic studies when antimicrobials are continued or changed because these values establish organ-function trajectory and affect treatment safety.[12]
- Record culture-positive events and susceptibility patterns for future empiric-antibiotic selection during recurrent fever episodes.[12][19]

*Monitoring targets that change reassessment or subsequent-cycle planning.[1][11][12][16][19]*

| Target | What to track | Why it changes management |
| --- | --- | --- |
| Clinical status | Vital signs, respiratory findings, mental status, new focal symptoms, and examination changes.[11][12] | New instability or a focal syndrome requires escalation of diagnostic and treatment intensity.[11][23] |
| Hematologic course | Serial ANC and duration of neutropenia.[1][19] | Persistent or anticipated severe neutropenia sustains infection risk and informs ongoing monitoring.[1][19] |
| Organ function | Renal function, liver tests, and electrolytes.[12] | Organ dysfunction affects antimicrobial safety and may signal severe infection or treatment toxicity.[12] |
| Microbiology | Blood, urine, wound, or other clinically indicated culture results and susceptibilities.[12] | Allows targeted therapy and informs empiric choices in future episodes.[12][19] |
| Future chemotherapy risk | Regimen intensity plus patient-specific risk factors and prior febrile neutropenia history.[11][16][22] | Guides oncology planning for subsequent-cycle supportive care and surveillance.[16] |

## References
1. Febrile neutropenia - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/950
2. Risk stratification in children with cancer and febrile neutropenia — www.thelancet.com — https://www.thelancet.com/pdfs/journals/eclinm/PIIS2589-5370(19)30219-6.pdf
3. Impact of time to antibiotics on clinical outcome in ... — www.thelancet.com — https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(24)00220-7/fulltext
4. Re-evaluating and recalibrating predictors of bacterial ... — www.thelancet.com — https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30138-3/fulltext
5. Risk stratification in children with cancer and febrile ... — www.thelancet.com — https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(19)30219-6/fulltext
6. Management of febrile neutropenia in low risk cancer patients — thorax.bmj.com — https://thorax.bmj.com/content/thoraxjnl/55/suppl_1/S63.full.pdf
7. A Double-Blind Comparison of Empirical Oral and ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJM199907293410501
8. Management of Fever in Patients with Cancer and ... — www.nejm.org — https://www.nejm.org/doi/pdf/10.1056/NEJM199305063281808
9. Management of Febrile Neutropenia in Pediatric Oncology | Cancer Therapy | Oncology and Carcinogenesis | Health sciences | Topics | Nature Index — www.nature.com — https://www.nature.com/nature-index/topics/l4/management-of-febrile-neutropenia-in-pediatric-oncology
10. Clinical profile, treatment, and outcomes of febrile neutropenia in hematologic disorders: a look at 30-day mortality predictors | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-025-06787-z
11. In-hospital mortality prognostication for cancer patients with febrile neutropenia | Communications Medicine — www.nature.com — https://www.nature.com/articles/s43856-025-01142-9
12. Microbiological profile and 30-day mortality outcomes in febrile neutropenia among solid malignancy patients: a multicentre retrospective study from resource-limited setting | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-025-22761-1
13. Emergency management of fever and neutropenia in children with cancer: A review - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0735675721007920
14. Approach to evaluation of fever in ambulatory cancer patients receiving chemotherapy: A systematic review - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0305737216301141
15. Oncologic Emergencies: The Fever With Too Few Neutrophils - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0736467919306614
16. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1040842813002618
17. Empirical Treatthent of Febrile Neutropenia — academic.oup.com — https://academic.oup.com/cid/article-pdf/24/Supplement_2/S256/1237018/24-Supplement_2-S256.pdf
18. 2014 Update by the Infectious Diseases Society of America — academic.oup.com — https://academic.oup.com/cid/article/59/2/e10/2895845
19. Clinical Practice Guideline for the Use of Antimicrobial Agents ... — academic.oup.com — https://academic.oup.com/cid/article/52/4/e56/382256
20. 2016 Update by the Infectious Diseases Society of America — academic.oup.com — https://academic.oup.com/cid/article/62/4/e1/2462830
21. Diagnosis and Management of Febrile Neutropenia in Pediatric Oncology Patients—A Systematic Review — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9394251
22. ESMO Clinical Practice Guideline: Febrile Neutropaenia — www.esmo.org — https://www.esmo.org/guidelines/esmo-clinical-practice-guideline-febrile-neutropaenia
23. Clinical prediction models for febrile neutropenia and its outcomes: a systematic review - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12137469
24. Update on Febrile Neutropenia in Pediatric Oncological ... - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8700030

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.